This study investigates the neuroprotective effects of a test compound on dopaminergic neurons overexpressing mutated alpha-synuclein in a rat embryo midbrain culture. The compound is shown to prevent toxic aggregation of alpha-synuclein, preserving neuronal structure and viability.
Start with a primary midbrain culture from rat embryos, containing dopaminergic neurons that overexpress mutated alpha-synuclein.
Replace the media in the treatment wells with fresh media containing the test compound, and that in the control wells with plain media. Then incubate.
In the control, alpha-synuclein forms toxic aggregates in dopaminergic neurons, causing neurite retraction and leading to neuronal death.
In the treatment, the test compound interacts with alpha-synuclein, prevents its aggregation, preserves neurite structure, and provides neuroprotection.
Fix and permeabilize the cells, then block non-specific binding sites.
Incubate with primary antibodies to label all neurons, with additional labeling for dopaminergic neurons.
Wash the cells and add fluorophore-tagged secondary antibodies specific to the primary antibodies.
Using an inverted fluorescence microscope, count the differentially-labeled dopaminergic neurons, then switch to a confocal microscope to measure neurite length.
A higher count of dopaminergic neurons with intact neurites in the treatment compared to the controls confirms the test compound’s neuroprotective potential.
繁體中文
